Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alpine Immune Sciences Inc
(NQ:
ALPN
)
64.60
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alpine Immune Sciences Inc
< Previous
1
2
3
4
Next >
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 11, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
August 10, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
July 19, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
June 07, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
June 01, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
May 26, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
May 24, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 12, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in May Investor Conferences
May 03, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
April 12, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event
April 05, 2022
From
Alpine Immune Sciences Inc.
Via
Business Wire
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
April 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
March 30, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in January Investor Conferences
January 04, 2022
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
December 16, 2021
From
Alpine Immune Sciences, Inc. and Horizon Therapeutics plc
Via
Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference
November 22, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting
November 08, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces $91 Million Private Placement
September 15, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces Participation in September Investor Conferences
September 07, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 10, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences
August 04, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)
June 30, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration
June 24, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Set to Join Russell 3000® Index
June 08, 2021
From
Alpine Immune Sciences, Inc
Via
Business Wire
Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting
June 04, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting
June 02, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer
June 02, 2021
From
Alpine Immune Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.